Click on each picture to be linked to matching website.
HeartWare® Ventricular Assist System
HeartWare Receives FDA Approval for HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation for Patients with Advanced Heart Failure.
November 20, 2012
First full-support, miniaturized ventricular assist device approved in U.S. designed to be placed in the pericardial space.
HeartWare International, Inc. (Nasdaq: HTWR; ASX: HIN), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it has received approval from the United States Food and Drug Administration (FDA) for the HeartWare® Ventricular Assist System as a bridge to heart transplantation in patients with end-stage heart failure.
The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device (up to 10L/min flow) designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HVAD pump, with sintered inflow cannula, weighs approximately 5 ounces and displaces a volume of approximately 50 milliliters. The HeartWare System is intended for use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure.
The HeartWare System is currently the leading ventricular assist device implanted in patients outside of the United States, having received CE Marking in the European Union in 2009, and Australian Therapeutic Goods Administration (TGA) approval in 2011.
Today, more than 2,500 advanced heart failure patients globally have received the HVAD® pump......read more
The Total Artificial Heart: Pumping Our Way Into the Future
Posted on AARS: November 15, 2012
The Total Artificial Heart: Pumping Our Way Into the Future. Challenges and Lessons Learned. Marvin J. Slepian, M.D.. Professor of Medicine & Biomedical ...
Mount Sinai Discharges 1st Artificial Heart Patient in the Metro Area
October 25, 2012
The first patient in the metropolitan New York area to be discharged with a Total Artificial Heart left The Mount Sinai Medical Center today. Twenty-eight-year-old Daquain Jenkins, who is awaiting a heart transplant, was implanted with the SynCardia temporary Total Artificial Heart in August. By relying on a mobile power supply that he carries in his backpack, Mr. Jenkins is able to leave the hospital until a suitable donor heart is found.
Mr. Jenkins is part of an FDA-approved Investigational Device Exemption (IDE) clinical study that is examining the Freedom® portable driver, a 13.5-pound wearable power supply for the total artificial heart. The portable driver provides enough power for the heart to last up to three hours from batteries before being recharged using an outlet or car charger. Patients receive an extra set of batteries for longer excursions.
Mr. Jenkins was diagnosed with congestive heart failure at age 25, when he went to the doctor near his home in Monticello, N.Y. complaining of symptoms of pneumonia. His father had died of heart failure at age 28. Mr. Jenkins started on medical therapy, which worked for a year before he started having symptoms again. He had a pacemaker and a defibrillator implanted at a local hospital, but his condition continued to worsen.
In April 2011, he had a heart transplant at Mount Sinai, but his body rejected the heart after a year. Because both sides of the donor heart were failing rapidly, and he was ineligible for a left ventricular assist device—a type of mechanical heart pump that is more commonly used to support left side heart failure.
"Daquain has recovered remarkably well from his surgery," said Dr. Nair. "We are pleased to give him the opportunity to spend time with his family and continue his schooling while he waits for a donor heart.".........read complete story
FDA expands approved use of Sapien artificial heart valve
October 19, 2012
The U.S. Food and Drug Administration today expanded the approved indication for the Sapien Transcatheter Heart Valve (THV) to include patients with aortic valve stenosis who are eligible for surgery, but who are at high risk for serious surgical complications or death.
The FDA first approved the Sapien THV in 2011 for patients with inoperable aortic valve stenosis, a progressive, age-related disease. Calcium deposits on the aortic valve that cause it to narrow are a common cause of aortic valve stenosis. As the heart works harder to pump enough blood through the smaller opening, it eventually weakens. Aortic valve stenosis can lead to fainting, chest pain, heart failure, irregular heart rhythms (arrhythmias), or cardiac arrest.
Those with severe aortic valve stenosis must have a heart valve replacement to restore normal blood flow. Patients who are in good enough health to tolerate surgery usually undergo open-chest, open-heart surgery or a minimally invasive surgery, in which surgeons gain access to the heart through an incision between the ribs.
The Sapien THV is implanted without opening the chest or heart. The device is compressed into a thin, flexible tube called a delivery catheter. The delivery catheter and the THV are inserted into the femoral artery through a small incision in the leg and threaded to the site of the diseased valve. The THV is then released from the delivery catheter and expanded with a balloon and is immediately functional.....read more
New Market Research Report "Global Artificial Organs Industry"
August 13, 2012
This report analyzes the worldwide markets for Artificial Organs in US$ Million by the following Product Segments: Artificial Heart, Artificial Kidneys, Artificial Liver, Artificial Pancreas, and Artificial Lungs. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets.
The report profiles 54 companies including many key and niche players such as Abbott Diabetes Care, Abiomed Inc., Asahi Kasei Kuraray Medical Co., Ltd., Baxter International, Inc., F. Hoffmann-La Roche Ltd., Fresenius Medical Care AG & Co. KGaA, Fresenius Medical Care North America, Inc., Fresenius Kawasumi, Gambro AB, HeartWare International, Inc., HepaLife Technologies, Inc., Alliqua, Inc., Jarvik Heart, Inc., MC3, Inc., Medtronic, Inc., MicroMed Cardiovascular, Inc., Nikkiso Co., Ltd., Nipro Corporation, SynCardia Systems, Inc., Terumo Corporation, Thoratec Corporation, Toray Medical Co., Ltd., Vital Therapies, Inc., and WorldHeart Corp.
Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
A Houston-led study has found that the world's first heart pump for babies and children provides a lifesaving bridge to transplantation, heralding a new era of care for pediatric heart patients.
Decades after heart pumps began extending the lives of adult cardiac patients, the study led by Texas Children's Hospital showed the miniature device known as the Berlin Heart kept 90 percent of children alive while they waited for a donor organ. Without the device, small children have little hope of surviving long once their hearts start failing.
The pump, manufactured in Germany and available in sizes to fit children from newborns to teenagers, connects to the heart through a pair of tubes and is run by a laptop computer to help the heart's ventricles pump blood to the lungs and the rest of the body.....complete article
Fishing vest with a pump keeps heart patients alive
Posted on AARS: August 7, 2012
They look like they’d fit into a laptop, but the 14-volt lithium-ion batteries Lewis Ball wears in a modified fishing vest are all that keep him alive.“Unplug them, and my pump’s going to stop,” Ball said. “And in a very short time, I’m going to stop.
“The Left Ventricular Assist Device, or LVAD, draws blood from his left ventricle with a turbine pump spinning at 9,200 revolutions per minute, and sends it into the aorta. The system can serve as a bridge to a heart transplant or heart recovery. But Ball is ineligible for a transplant. The system will be with him for the rest of his life.
The vest, made for him by a Missoula seamstress, has pockets for the two batteries and a computer controller that operates the pump. He carries a second set of batteries and emergency instructions with him wherever he goes.
When the device was implanted in Ball’s chest last December at the Mayo Clinic in Rochester, Minn., the staff and volunteers gave him and his wife Frances hours of training and support. Now he’s hoping to do the same for the other LVAD patients. But because of federal confidentiality laws, they will have to contact him. “I understand there’s between five and nine other patients in this area,” he said, “but I don’t know what this area includes.
”Based on the model set by Mended Hearts, he wants to start a support group that focuses on the unique needs of LVAD patients and their families. According to the American Heart Association, almost 600 devices were implanted in 2010, with the numbers rising each year. “I want to start this help group, because I don’t really need much help. It’s the caregivers I’m concerned about, because all the stress is on them,” Ball said.
The group will either be a subset of the local Mended Hearts chapter, or freestanding, depending on the wishes of the members.
“I’ve been given some privileges,” Ball said., along with a model heart from Missoula Rural Fire that he uses for training. Using the model heart and a model pump, he conducts training sessions for anyone interested.
For anyone interested in joining this support group please contact:
Joanna Wilson, a journalism student at the University of Idaho and a Missoulian intern. She can be reached at 406-523-5251.
Group pumps $30 million into Cleveland Heart plan
August 3, 2012
Cleveland Heart Inc. has received a $30 million investment that will aid efforts to bring its version of the total artificial heart to market.
Cleveland Heart Inc. is a joint venture between Charlotte-based Trans-World Medical Devices and Cleveland Clinic Foundation, the corporate venture arm of the Cleveland Clinic.
The investment was made by a Korean private-equity group, known as the Power Heart Consortium. Further details were not available.
Cleveland Heart says the money will be used for further development and clinical trials for its artificial heart. The device will replace a patient’s heart prior to a transplant.....read more
Artificial jellyfish engineered out of rat heart muscles
Posted on AARS: July 23, 2012. Story by John Roach, contributing writer for NBC News
Scientists have made an artificial jellyfish out of rat heart muscles and rubbery silicon. When given an electric shock, it swims just like the real thing. Future versions should be able to swim and feed by themselves. “That then allows us to extend their lifetime,” John Dabiri, a professor of aeronautics and bioengineering at the California Institute of Technology, told me.The breakthrough is a big step toward the development of an artificial human heart with living cells. It also opens a window to a future where humans could loosen the constraints of evolution.
The first full implantation of an artificial heart has been made in Kazakhstan, Tengrinews.kz reports citing the press-service of the National Medical Holding.
“There is still no organs transplantation in our country. Our doctors are ready for it, both the general surgeons and the cardiac surgeons, i.e. the medical parts of the issues are solved. Everything else is in place. But there are social, legal and moral issues. Our society is not ready for organs donorship and the mentality does not allow to widely implement it. But, despite of these problems, there are patients and we have to treat them. Installation of the artificial heart is currently one of the solutions,” Yuriy Pya said.
What makes the surgery so special is that this is the third such surgery in the world. The first one was made in Germany, the second one in the U.S. and the third one in Kazakhstan. The artificial heart was implanted to a 61-y.o. citizen of Astana suffering from a heavy abnormity of the heart-vascular system.
During the surgery the surgeons fully removed his right and left ventricles and implanted two HEARTWARE pumps for artificial blood flow to the atriums. The pumps can pump up to 10 liters of blood per minute, which complies with the normal heart work.
“The patient is currently stable. His body still has to adapt. This is a complicated surgery,” Yuriy Pya said at the press-conference.....read more
FDA reviews safety of innovative heart valve
June 11, 2012
Federal health officials are asking safety questions about the first artificial heart valve designed to be implanted without major surgery, ahead of a meeting this week to consider broadening its use.
Last summer Edwards Lifesciences Corp. won approval for its first-of-a-kind Sapien heart valve, which can be threaded into place through one of the body's major arteries. The valve is currently available for patients who aren't healthy enough to undergo the more invasive open-heart surgery which has been used to replace the valve for decades.
Now the Food and Drug Administration is considering expanding the device to patients who are healthier, but still face serious risks from chest-opening surgery. Many such patients are in their 80s and have complicating medical factors like diabetes.
In an online review posted Monday, FDA reviewers said the heart valve compared favorably to surgery after one year, with patients living about the same amount of time. In Edwards' study submitted to the agency, 24 percent of patients implanted with the heart valve died after one year, compared with 27 percent of those who had undergone surgery. The numbers were close enough to meet the study's goal of showing that the valve was at least as effective as surgery.....read more
Agonising wait: Llana was at the top of the emergency transplant list for four months
Heart transplant baby girl returns home after four months being kept alive on series of mechanical hearts
June 6, 2012
When baby Llana began struggling to sleep and feed properly in September, her concerned mother, Shaz, 39, took her to the doctors. Tests at South Tyneside District Hospital revealed she had a murmur on her heart and she was transferred to Newcastle’s Freeman Hospital for specialist treatment.
There she was diagnosed with cardiomyopathy, which affects the heart muscles and meant her heart was not strong enough to work on its own. Mrs Qazi and her husband Muhammed, 47, were told Llana urgently needed a heart transplant. While the family faced a terrifying wait, Llana was put on a Berlin Heart - a machine that helps the left side of the heart pump blood around the body. She required a further four artificial heart machines as doctors could not keep her stable.
The family waited desperately for news of a donor, and their prayers were answered on February 29 when they received a call that a suitable heart had been found.But doctors warned Llana had a 50/50 chance of survival. The operation was an initial success but Llana’s life hung in the balance after her new heart stopped for 63 minutes a day after the transplant.
Llana’s lungs collapsed and she went into cardiac arrest. She was also placed in isolation more than once after her rejection levels soared sky-high. After spending three months recuperating on the Children’s Heart Unit at the Freeman Hospital, she has now returned home and can get to know her five brothers and sisters.....read more
Creating an ideal "off-test mode" for rotary left ventricular assist devices: Establishing a safe and appropriate weaning protocol after myocardial recovery.
Posted: May 17, 2012
Objective: Recent developments in adjunctive therapy have enabled us to remove once-implanted left ventricular assist devices. For successful device removal, appropriate patient selection and precise evaluation of cardiac function are essential. However, with rotary pumps, pump weaning inevitably creates diastolic retrograde pump flow, and this flow may overload the native heart. We developed a novel "off-test mode" for weaning, which increases revolutions per minute just in diastole. The present study evaluated the effect of this mode on retrograde pump flow and ventricular workload.
Methods: The EVAHEART device (Sun Medical Technology Research Corporation, Nagano, Japan) was installed in 8 goats (63.0 ± 7.3 kg). We evaluated myocardial oxygen consumption, pressure volume area, and retrograde pump flow under 3 conditions: circuit clamp, continuous mode, and off-test mode. In continuous mode, revolution per minute was set for a mean net pump flow of zero, whereas in off-test mode, systolic revolution per minute was kept at a minimum level and diastolic revolution per minute was adjusted to ensure near-zero diastolic retrograde pump flow.
Medtronic, Maquet, Edwards Capitalize on Untapped Chinese Cardiac Surgery and Heart Valve Market
May 14, 2012
According to a new report by iData Research (www.idataresearch.net), the leading global authority in medical device market research, the Chinese cardiac surgery market will almost triple in value by 2018 due to high double-digit growth rates of tissue heart valves, on-pump coronary artery bypass devices (ONCAB) and endoscopic vessel harvesting devices. The Asia-Pacific cardiac surgery market, which includes Japan, South Korea and Australia, is also expected to see strong growth within the tissue heart value, ventricular assist device (VAD) and artificial heart segments.
"Access to healthcare in China has been greatly facilitated by the rapidly growing economy, opening up huge untapped healthcare markets," says Dr. Kamran Zamanian, CEO of iData. "In addition, China is the world's largest consumer of tobacco products followed closely by Japan. This is leading to higher rates of cardiovascular disease and heart attacks and fueling the market for cardiac surgery devices. Companies such as Medtronic, Maquet and Edwards Lifesciences are moving in to capitalize on these lucrative segments.".....read more
SENDAI — A research team at Tohoku University has developed a wireless mechanical heart pump, moving a step nearer to developing the world's first fully embedded artificial heart.
The newly developed pump is roughly as big as a C-size battery and can pump more than 5 liters of blood per minute — similar to a human heart's capacity — through a spinning cylindrical magnet, according to professor Kazushi Ishiyama, who headed the team.
The pump can be operated by holding a separate device over the skin to generate magnetic force. Owing to the new pump's small size and simple structure, an artificial heart using the pump will also be less costly, Ishiyama said. Conventional mechanical pumps are too large to be embedded in the human body and need to be connected to an electrical cord routed through a patient's skin.
An artificial heart using the pump was successfully tested on animals. The team will continue testing the system on animals before conducting a clinical trial with humans researchers said.
A team of seniors designed and built a transcutaneous energy-transfer (TET) unit to power a minimally invasive ventricular assist device (VAD)
Skin no barrier for cardiac charger
Posted: May 4, 2012
Rice University seniors devise wireless energy-transfer device for tiny heart pump
Heart-failure patients may someday get a life-saving charge from technology developed by students at Rice University. A team of seniors designed and built a transcutaneous energy-transfer (TET) unit to power a minimally invasive ventricular assist device (VAD) being created by Houston based Procyrion.
Michael Torre, Erin Watson, Tyler Young, Trevor Mitcham, Hana Wang and Alex Dobranich (Team TCoil) made a complementary device that sits a centimeter under the skin and feeds power to the VAD. The challenge presented to the seniors, who were required to complete a capstone design project by Rice’s George R. Brown School of Engineering , was to charge the unit wirelessly.
The students’ prototype consists of a small coil and a battery that would be inserted one centimeter under the skin at the patient’s waist and wired to the VAD. The patient would also wear a belt-mounted external battery and coil to generate alternating magnetic fields and induce alternating current in the subcutaneous coil. The coils charge the battery, which can operate the pump for more than three hours.
“The patient can take the belt off for a short time, to take a shower, for instance,” Young said. “The pump will work safely off the coils or on the internal battery alone, but obviously it’s best when they’re both working.”....read more
Jayden Villano, 19 months, held by his mother Alexa Guiterrez, is heading back home to Wellington after finally receiving a donor heart.
Heart pump, transplant save Wellington toddler's life
April 27, 2012
Jayden Villano is crawling around Joe DiMaggio Children's Hospital's Family Resource Center like most 19-month-old toddlers would, playfully pushing a small yellow ball while holding a colorful barn in his tiny hands.
Sitting nearby, Alexa Guiterrez, Jayden's mom, smiles as tears begin to well up in her eyes.It's easy to understand why.
Six months ago, Jayden was near death, suffering from end-stage heart failure and dilated cardiomyopathy, a condition in which the heart becomes weakened and can't pump blood effectively.
"He was a ticking time bomb," said Guiterrez, 24, a Wellington resident.
Jayden was immediately put on the list for a heart transplant. But while he waited for a suitable donor, doctors implanted the Berlin Heart, which Jayden used for 140 days. The device performed the job of a left ventricle by sucking blood from the ventricle and pumping it into his aorta. Doctors at Joe DiMaggio Children's Hospital said Jayden is the first person in South Florida to receive and be supported until transplant with the Berlin Heart.
Fortunately for Jayden, a donor was found this month, a little girl. Jayden received his new heart April 3 during a 4½ -hour procedure. He was discharged from the hospital six days later.
Today, Jayden is alive and playing, thanks to the donated heart he received this month. He's also alive thanks to the Berlin Heart, a temporary blood-pumping device used for babies and children until a donor heart becomes available.....complete article
FDA Approves HUD Designation for Destination Therapy for SynCardia’s Total Artificial Heart
April 12, 2012
Approval of HDE Will Allow Up to 4,000 U.S. Patients Not Eligible for Transplant to Receive the Total Artificial Heart on a Permanent Basis
SynCardia Systems, Inc., manufacturer of the world’s first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that the U.S. Food and Drug Administration (FDA) has approved a Humanitarian Use Device (HUD) designation for the SynCardia temporary Total Artificial Heart to be used for destination therapy in addition to its current PMA approval as a bridge to transplant.
“This is a huge milestone that with approval of our HDE, will allow the Total Artificial Heart to save the lives of up to 4,000 U.S. patients each year who are not eligible for transplant,” said Michael Garippa, SynCardia Chairman/CEO/President.
The FDA approval letter of the HUD request designates the Total Artificial Heart for use in U.S. patients “at risk of imminent death from non-reversible biventricular heart failure who are not eligible for cardiac transplant and have a body surface area (BSA) of ≥ 1.7m2.” SynCardia is preparing a Humanitarian Device Exemption (HDE) to submit to the FDA.....read more
SynCardia temporary Total Artificial Heart
URMC Surgeons Implant 1st Total Artificial Heart in Upstate New York
April 11, 2012
The University of Rochester Medical Center cardiac transplant team has replaced a 49-year-old man’s heart with a total artificial heart, introducing a new, life-sustaining treatment option for the most critically ill patients with end-stage heart failure.
The total artificial heart is a bridge to transplant for patients who suffer from end-stage biventricular heart failure, a condition in which both sides of the heart become weakened and cannot pump blood adequately throughout the body. More than 1,000 have been used in patients worldwide to date.
To implant the SynCardia device, surgeons remove the left and right ventricles and valves of the heart, leaving the left and right atria, aorta and pulmonary artery intact.....read more
Artificial heart keeps boy alive for record 251 days
April 10, 2012
A three-year-old boy has been kept alive with an artificial heart for more than eight months, which doctors say is a record for a child in the UK.
Joe Skerratt from Gillingham, Kent, was diagnosed with dilated cardiomyopathy, which meant his heart struggled to pump blood around his body.He was temporarily fitted with a "Berlin heart", to give his own a helping hand.After 251 days, he finally had a heart transplant last year.
Joe's mother, Rachel, said "we started to see his character coming back" after he was fitted with the Berlin heart. But this was the start of a long wait for a heart donor.
"When Joe passed the 200-day mark on the Berlin heart we started to really question what else could be done if a heart wasn't found, but we knew deep down there wouldn't be much," she said."On day 251 the call we had been waiting for came......read more
Queensland University of Technology Professor Andy Tan examines the new counter-flow heart pump under development. (Credit: Queensland University of Technology)
Heart Pump Design Could Give Patients New Hope
From ScienceDaily (Apr. 10, 2007) - Posted on AARS: April 9, 2012
A new counter-flow heart pump being developed by Queensland University of Technology has the potential to revolutionize future designs of the mechanical heart. Lead researcher Associate Professor Andy Tan said the heart pump's innovative design was based on a double-output centrifugal model that pushed the blood in a counter direction to ensure correct flow through both sides of the heart, and is the subject of a patent application.
"The counter-flow pump is a bi-ventricular assist device (BVAD), meaning it supports both the left and right sides of the heart simultaneously," he said. "But what's so groundbreaking is that it is the first device to combine the function of two pumps into one unit.....
HeartWare International Expands Intellectual Property and Technology Portfolio Through Definitive Agreement to Acquire World Heart Corporation for US$8 Million
March 29, 2012
/PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR, ASX: HIN), which develops and manufactures miniaturized ventricular assist devices, and World Heart Corporation (NASDAQ: WHRT), which has been engaged in the development of left ventricular assist devices, announced today that they have entered into a definitive merger agreement under which HeartWare will acquire WorldHeart for consideration of US$8 million, which will be paid in shares of HeartWare common stock or cash, at HeartWare's election.
"WorldHeart has been an important participant in the development of ventricular assist therapies for many years and has amassed over one hundred patents and patent applications. In line with our goal to be a leader in the VAD market for years to come, we believe that bolstering our patent portfolio and adding WorldHeart's technologies broadens our options for the future," said Doug Godshall, President and CEO of HeartWare. "While we are intensely focused on the FDA panel for our HVAD® System next month, and commencement of first-in-man studies for our MVAD® System mid-year, we look forward to integrating WorldHeart's technologies and members of its talented team into our research efforts."....read more
Technological breakthroughs provide a new release: The doctor who fitted a pacemaker in the brain to treat epilepsy
Posted: March 27, 2012
Dr Alok Gupta, HOD, neurosurgery, Artemis Health Institute can be credited for using a pacemaker in the brain to treat epilepsy for the first time in India.
While a pacemaker is typically used to control abnormal heart rhythms, it's latest use involves controlling epileptic seizures.
This procedure was done on 33 year old Shalini Arora, who is the first epileptic patient in India on whom a pacemaker has been implanted. Shalini had been suffering from this neurological disorder since she was an 18 month old. "Epilepsy paralyses people by affecting their day to day life as fits can occur any time of the day," says Dr Gupta.
Before the pacemaker was implanted, Shalini's days began with bouts of fits because the kind of epilepsy she suffers from cannot be controlled by medicines alone.
"About fifteen per cent of epilepsy cases cannot be treated with medications. In these cases the conventional treatment just doesn't work as a wide area of the brain is affected. That's when deep brain stimulation can work," says Dr Gupta.
He performed this highly specialised procedure using the keyhole technique to implant a pacemaker into Shalini's brain. "A wire as thin as a hair is implanted in the brain. The area acts as a gate, controlling electrical discharges to and from the brain and the limbs. The pacemaker is implanted below the left collar bone," explains Dr Gupta.
For the first time in her life, Shalini is feeling well enough to tackle life on her own terms and is now eager to finish her masters. "The pacemaker has helped as she hasn't had any seizures for the last six weeks since the procedure," says Dr Gupta.
Building an artificial heart with ferrofluids
March 27, 2012
Chris Suprock, from Suprock Technologies, Exeter, NH, is developing an artificial heart he calls Steel Heart. It’s an artificial heart powered by electromagnets and ferrofluids.
The idea behind [Chris]‘ artificial heart is ingenious in its simplicity. An elastic membrane is stretched across a frame and a magnetic liquid (or ferrofluid, if you prefer) is poured across the membrane. An electromagnet is activated and the membrane stretches out, simulating the beating of a heart. Put a few of these together and you’ve got a compact, biologically inert pump that’s perfect for replacing an aging ticker.
Previously, artificial hearts used either pneumatics or motors to pump blood throughout the body. Pneumatic pumps required plastic tubes coming out of the body – not a satisfactory long-term solution. Motor-driven pumps can rupture red blood cells leading to hemolysis. Using ferrofluids and an elastic membrane allows for the best of both worlds – undamaged blood cells and transdermal induction charging.
View [Chris]‘ indiegogo video with a demo of the ferrofluid pump in action after the break.
Chris Suprock is in the Systems Engineering PhD program at the University of New Hampshire and can be reached at Suprock Technologies, Exeter, NH.
We're exploring a new type of artificial heart pump using magnetic fluids to replicate the motion of natural muscle.
Former Vice President Richard B. Cheney doing ‘exceedingly well’ after heart transplant
Posted: March 27, 2012
Cheney, 71, had the operation at Inova Fairfax Hospital in Northern Virginia, where surgeons had implanted a battery-powered “left-ventricular assist device” (LVAD) in 2010.
“He’s doing terrific,” said Jonathan Reiner, Cheney’s longtime cardiologist at George Washington University Hospital, which does not have a transplant program. Reiner said he saw the former vice president Sunday morning and “he joked with me. He was doing exceedingly well.”
The transplantation is the latest chapter in the semi-public chronicling of Cheney’s life with coronary heart disease, the leading cause of death in the United States.
Cheney’s chance of surviving for years with a good quality of life is high, although his predicted longevity depends on how one looks at his medical history.
For example, according to data compiled by the Texas-based International Society for Heart & Lung Transplantation, about 60 percent of people age 70 and over at the time of their heart transplant live at least six years. About 80 percent of people getting transplants because of heart damage caused by coronary disease survive that long. About 70 percent of people who have the kind of mechanical device Cheney did — a continuous-flow LVAD — survive at least six years after they get a new heart. (The data describe the experience of people who got surgery from 2002 to 2009).....read more
Indianapolis Doctors Developing 1st Heart Pump For Babies
March 20, 2012
Indiana researchers are on the cutting edge of developing the first heart pump for babies.
Artificial heart pumps have come a long way since they were approved for adults more than a decade ago, but there still isn't a pump for babies born with one heart chamber instead of two, RTV6's Stacia Matthews reported.
It's the leading cause of death from birth defects in babies, and only between 50 percent and 70 percent of infants survive the three open heart surgeries required to fix the problem.
"Our current treatment is good, but it's not perfect, and if this technology is developed, it could really change things around the world," said Dr. Mark Rodefeld, a researcher with the IU School of Medicine who is developing the infant pump.
Using the concept of a spinning top, the device pulls blood from the veins and pushes it into the arteries.
"Blood flow would be coming in this way and going out to the lungs that way, and there's never been a blood pump developed that would do this four directions of flow," Rodefeld said. Babies would wear the pump temporarily, and those who do may not require so many operations.......read more
Poway Woman Receives Rare Artificial Heart
Posted: March 19, 2012
Michelle Johnson, 38, is only the 24th person in the world to receive a battery-powered artificial heart.
Johnson depends on the device that, from the outside, looks similar to a backpack. But it's what is inside the backpack that allows the mother of three to continue living.
She was diagnosed with congenital heart failure and her body recently rejected a previous heart transplant. Her only hope was an artificial heart, so doctors implanted the SynCardia Heart Pump. The tubes connect her body to the backpack, allowing blood to flow.
"Now patients can go home with a 13-pound device either on their back or as a carry-on," said Dr. Jaime Moriguchi of Cedars-Sinai Medical Center in Los Angeles.
Johnson was the first heart patient at Cedars-Sinai Medical Center in Los Angeles to undergo the procedure. She said she most looks forward to being with her three children, and said her youngest son cannot wait for his mother to come home.......read more
Zack Poe. (Photo courtesy of UK Hospital)
The world's first and only FDA, Health Canada and CE (Europe) approved Artificial Heart Implanted at UK Hospital
Dr. Mark Plunkett, chief of Cardiothoracic Surgery at the University of Kentucky, says the artificial heart is a bridge until a transplant is ready.
“The device is a polyurethane device. It has two pumps, each driven by its own drive line, and it has four mechanical valves,” he said.
The patient is 20-year-old Zack Poe of Maysville. Doctors diagnosed his heart failure in January.
“I feel a million times better. Because of the outflow volume, I’ve been able to walk longer without pain than I have in months,” Poe said.
Zack Poe, 20, is the first patient in the state to leave the hospital to wait for a matching donor heart at home using the Freedom® portable driver to power his Total Artificial Heart.
Only 29 medical centers across the country are certified to perform the artificial heart procedure.
UWI scores big with heart surgery simulator
February 27, 2012
Top US hospitals request prototype, says Prof Shirley
THE cardiac surgery simulator (CSS), a device developed at the University of the West Indies (UWI) and used to train students in doing heart surgery, has generated interest from some of the leading hospitals in the United States.
According to UWI Mona principal Professor Shirley, the University of North Carolina, Johns Hopkins, the Mayo Clinic, the University of Washington, Stanford University and the University of Southern California, have all requested prototypes of the CSS, which was developed by UWI-trained surgeon Dr Paul Ramphal and computer scientist Dr Daniel Coore.
Prof Shirley explained that the CSS uses a computer to pump synthetic blood around an artificial heart. The heart can be altered to simulate certain cardiac conditions.
The CSS allows medical students to practice on artificial hearts instead of real cardiac patients.
"This is a fabulous way to get students to train and become experts before they actually do the surgery," Prof Shirley noted.....read more
Allegheny General Hospital doctors announce heart transplant breakthrough
February 23, 2012
Physicians at Allegheny General Hospital said today they replaced a failing human heart with the newest version of a total artificial heart. Unlike earlier models made popular in the 1980s, the newest mechanical heart is powered by a portable pump that allows patients to return home to await a heart transplant.
The device, called the SynCardia Temporary Total Artificial Heart replaces both ventricles of the heart, unlike traditional heart pumps that assist one side of the heart. To implant the device, surgeons remove the left and right ventricles and the four natural valves of the heart, leaving the left and right atria, aorta and pulmonary artery intact, officials said.
Typically, the artificial heart is powered with air and vacuum provided by a machine weighing 400 pounds, forcing patients to remain hospitalized. AGH is one of 30 medical centers in the United States participating in the clinical trial of SynCardia's portable system, which allows patients to leave the hospital. The pump weighs slightly more than 13 pounds and may be carried by the patient in a backpack or shoulder bag.
Nationwide, 23 people have so far used the portable device. The longest time anyone has been supported by a SynCardia total artificial heart is 46 months.....complete article
Keeping a steady heartbeat -- with mechanical help
Posted: February 20, 2012
Heart pumps are mechanical devices thatcan keep people with advanced heart failure alive while they wait for a heart transplant. The devices are getting better. The left ventricular assist device, or LVAD system, may one day be smaller and completely implantable, making it a game changer, experts say, for advanced heart failure treatment.
The total artificial heart by SynCardia Systems Inc., a different device, is also getting streamlined. A version available now allows patients to go home while they wait for a heart transplant.
"I really wish that this photo contributes to increase the awareness of the current lack of donor organs." - Horst Wackerbarth -
Five-year-old Berlin Heart patient included in photography artist Horst Wackerbarth´s „Gallery of mankind“ February 7, 2012
Horst Wackerbarth, a worldwide famous photography artist is travelling around Europe with his red couch in order to take pictures of people of various cultures. For the first time he recently took his couch to Bad Oeynhausen where Dr. Eugen Sandica, chief surgeon at the Heart and Diabetes Center Bad Oeynhausen, and his young heart failure patient Tobias sat down. For five-year-old Tobias, the photo-shooting with Horst Wackerbarth was a most welcome distraction. The roof of the Heart and Diabetes Center Bad Oeynhausen, where Tobias is currently being treated served as a suitable scenery. The young patient is suffering from severe heart failure and is desperately awaiting transplantation. As his own heart would not be able to fulfill the necessary pump function until a suitable donor heart becomes available, the mechanical heart assist device EXCOR® Pediatric takes care of it.
55 year old Craig Lewis lived for five weeks without a heartbeat or a pulse
Meet the world's first HEARTLESS man who was able to live for five weeks without a pulse February 4, 2012
In March of last year, Craig Lewis, 55, was dying from a heart condition that caused build-ups of abnormal proteins, and not even a pacemaker could help save his life.
But two doctors from the Texas Heart Institute proposed a revolutionary new solution – install a ‘continuous flow’ device that would allow blood to circulate his body without a pulse.
Dr Billy Cohn and Dr Bud Frazier installed the device after removing Mr Lewis’ heart. Within a day, the patient was up and speaking with physicians.
"Tetherless" power-transmission technology could radically change LVAD therapy February 3, 2012
Ft Lauderdale, FL- Engineers have been trying to create a completely implantable ventricular assist device (VAD) that has no cords or vents transecting the skin since the earliest days of VAD and artificial-heart development. Now that vision appears more realistic than ever before because of the new generation of wireless power-transfer technologies.
Currently, infections are common in VAD patients because the device is powered by an external battery through a cable that runs through the skin. "Drive-line infection is the number-one problem with these devices, and I think it's a bigger problem than people realize," Dr William Cohn (Texas Heart Institute, Houston) told heartwire following a presentation on the new generation of transcutaneous energy-transfer systems at the Society of Thoracic Surgeons (STS) 2012 Annual Meeting.
"There are people who have had pumps for seven years with no problem, but by and large, if you've had a pump for a year, there's a 70% chance you'll get an infection," and the drive line transecting the skin is the major source of those infections, he said. Cohn also believes that a lot of the embolic events and strokes suffered by VAD patients are likely related to these infections....read more
Scientists have created an artificial heart tissue from the silk of the tropical tasar silkworm; they have used this silk to manufacture coin-sized discs for the affected heart tissue. Image: Max Planck Institute
Scientists Create Artificial Heart Tissue from Silk Posted: January 31, 2012
The silk has reportedly been used to manufacture coin-sized discs for affected heart tissue. It is hoped this artificial tissue can help repair damaged heart muscles.
Any medical expert will confirm that the human heart is tuned for performance and efficiency. It pumps blood to all parts of the body and under different physical and environmental conditions for several decades. This degree of continuous activity, particularly if further endangered by heart attacks or similar complications, can weaken heart cells and tissues, leading to scarring and eventually death.
The Max Planck study, which was conducted in association with an Indian team of scientists in Kharagpur, sought alternative materials with which to fashion replacement tissue samples....read more
Baptist Health Care and Cardiology Consultants using breakthrough technology January 26, 2012
Baptist Health Care and Cardiology Consultants have begun offering Impella – the world’s smallest heart pump.
Dr. Luther I. Carter, interventional cardiologist with Cardiology Consultants, recently performed the first procedure using this breakthrough technology.
“The catheter-based heart pump relieves the heart’s pumping function by providing temporary support that allows physicians the time needed to perform life-saving interventions,” Carter said. “This tiny device acts almost like an artificial heart as it maintains blood flow through the body during a cardiac procedure.”.....read more
Heart surgeon Dr. Ivan Knezevic is pictured with Slovenia's first Total Artificial Heart patient Nikola Gaspic
Slovenia's 1st Total Artificial Heart Patient Discharged from UMC Ljubljana Using the Freedom® Portable Driver January 19, 2012
SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the SynCardia temporary Total Artificial Heart, announced today that on Dec. 29, 2011, University Medical Center (UMC) Ljubljana discharged Slovenia's first Total Artificial Heart patient, 61-year-old Nikola Gaspic, to wait for a matching donor heart at home using the Freedom® portable driver.
"The Total Artificial Heart was the perfect solution to bridge this patient to a transplant because he had a ventricular septal defect (VSD). For which, there are no other effective treatments," said Dr. Ivan Knezevic, Director of the Transplant and Mechanical Circulatory Support Program in the Department of Cardiovascular Surgery at UMC Ljubljana.
The implant surgery was performed by Dr. Knezevic and proctored by experienced Total Artificial Heart surgeon Dr. Latif Arusoglu. It was the first implantation of SynCardia's Total Artificial Heart in southeastern Europe....read more
Cardiac Assist Devices Market to 2017 - Increasing Uptake of Ventricular Assist Devices and Total Artificial Heart to Drive Growth NEW YORK, Jan. 12, 2012 /PRNewswire/
GBI Research's report, "Cardiac Assist Devices Market to 2017 - Increasing Uptake of Ventricular Assist Devices and Total Artificial Heart to Drive Growth" provides key data, information and analysis on the global cardiac assist devices market. The report provides market landscape, competitive landscape and market trends information on three cardiac assist devices market categories – Ventricular Assist Devices (VAD), Intra-Aortic Balloon Pumps (IABP) and Total Artificial Heart (TAH).
The report provides comprehensive information on the key trends affecting these categories, and key analytical content on the market dynamics. The report also reviews the competitive landscape with major acquisitions and mergers in the last six years and a detailed analysis of the pipeline products in each category. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.....read more
Any medical information published on this website is intended purely as a informational tool only and is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional.
The Copyright of all images and documents is by the According Developing Group, Institute, Editor or Company. We only included data and images freely accessible. We have linked each image and/or story back to it's original source. If you want your system or certain information on it removed from our website, please contact us at email@example.com